natgillin/translations-raw huggingface dataset:
As cases of tuberculosis have been reported in patients treated with Remicade, you will be screened for tuberculosis before starting Remicade.
Pri bolnikih, zdravljenih z zdravilom Remicade, so poročali o primerih tuberkuloze, zato se pred začetkom zdravljenja z njim opravi presejalna preiskava na tuberkulozo.
This includes a thorough medical history and it is very important that you tell your doctor if you have ever had tuberculosis, or if you have been in close contact with someone who has had tuberculosis.
Zdravnik vas bo tudi temeljito izprašal o preteklih boleznih in zelo pomembno je, da mu poveste, če ste imeli kdaj v preteklosti tuberkulozo ali bili v tesnejšem stiku s tuberkuloznim bolnikom.
In addition, you will have a tuberculin skin test and a chest X-ray.
Opravljena bosta še tuberkulinski kožni test in rentgensko slikanje prsnega koša.
Your doctor must record the conduct of these tests on your alert card.
Zdravnik mora vpisati te preiskave na vašo opozorilno kartico.
If symptoms of tuberculosis (persistent cough, weight loss, listlessness, fever), or any other infection appear during therapy notify your doctor immediately.
Če se v času zdravljenja pojavijo simptomi tuberkuloze (trdovraten kašelj, hujšanje, nemir, zvišana telesna temperatura) ali katere druge okužbe, nemudoma obvestite svojega zdravnika.
Advise your doctor if you are a carrier of the hepatitis B virus (HBV), if you have active HBV or if you think you might be at risk of contracting HBV.
Če ste prenašalec virusa hepatitisa B (HBV), če imate aktivno okužbo z virusom HBV ali če menite, da obstaja pri vas tveganje za okužbo z virusom HBV, morate to povedati svojemu zdravniku.
Remicade can cause reactivation of HBV in people who carry this virus.
Zdravilo Remicade lahko povzroči reaktivacijo HBV pri bolnikih, ki so prenašalci tega virusa.
In some rare cases, especially if you are taking other medicines that suppress the immune system, reactivation of HBV can be life-threatening.
V nekaterih primerih, še posebej če jemljete tudi druga zdravila, ki zavirajo imunski sistem, je lahko reaktivacija HBV smrtno nevarna.
If you have recently received, or are scheduled to receive a vaccine, please inform your doctor.
Če ste bili pred kratkim cepljeni ali boste cepljeni, obvestite svojega zdravnika.
If you are about to undergo surgery or dental procedures please inform your doctor or dentist that you are taking Remicade.
Če je pri vas načrtovan kirurški ali zobozdravstveni poseg, povejte zdravniku ali zobozdravniku, da prejemate Remicade.
If you have mild heart failure and you are being treated with Remicade, your heart failure status must be closely monitored by your doctor.
Če imate blago srčno popuščanje in se zdravite z zdravilom Remicade, mora vaš zdravnik skrbno spremljati vaše stanje.
If you develop new or worsening symptoms of heart failure (for example shortness of breath, or swelling of your feet), you must contact your doctor immediately.
Če se pojavijo novi znaki srčnega popuščanja ali se obstoječi znaki poslabšajo (npr. težave z dihanjem ali otekanje nog), nemudoma obvestite svojega zdravnika
On rare occasions, you may develop signs and symptoms of a disease called lupus (persistent rash, fever, joint pain and tiredness).
V redkih primerih se lahko pojavijo znaki in simptomi bolezni, ki se imenuje lupus (trdovraten izpuščaj, zvišana telesna temperatura, bolečine v sklepih in utrujenost).
If these symptoms occur, contact your doctor.
Če se pojavijo ti simptomi, obvestite svojega zdravnika.
Before you use Remicade, tell your doctor if you have had lymphoma (a type of blood cancer) or any other cancer.
Preden začnete uporabljati zdravilo Remicade, povejte svojemu zdravniku, če imate ali ste imeli kdaj v preteklosti limfom (vrsta krvnega raka) oziroma katerokoli drugo vrsto raka.
If you take Remicade, your risk for developing lymphoma or another cancer may increase.
Če jemljete zdravilo Remicade, se lahko pri vas poveča tveganje za pojav limfoma ali katere druge vrste raka.
You should also tell your doctor if you develop lymphoma or other cancers while you are taking Remicade.
Svojemu 44 zdravniku morate povedati tudi, če se med jemanjem zdravila Remicade pri vas pojavi limfom ali katera druga vrsta rakave bolezni.
Reports of lymphoma in patients on Remicade are rare but occur more often than expected for people in general.
Poročila o pojavu limfoma pri bolnikih, ki jemljejo zdravilo Remicade, so redka, vendar pogostejša kot bi pričakovali pri ljudeh na splošno.
A patient with more serious rheumatoid arthritis who has had the disease for a long time may be more prone to develop lymphoma.
Bolniki z resnejšo obliko revmatoidnega artritisa, ki imajo to bolezen že dolgo časa, so lahko bolj nagnjeni k nastanku limfoma.
42 Some patients with Crohn's disease or ulcerative colitis who have received Remicade have developed a rare type of cancer called Hepatosplenic T-cell Lymphoma.
Pri nekaterih bolnikih s Crohnovo boleznijo ali ulceroznim kolitisom, ki so prejemali zdravilo Remicade, se je pojavila redka oblika raka, ki mu pravimo hepatosplenični limfom T celic.
Most of these patients were adolescent or young adult males.
Večina teh bolnikov je sodila med mladostnike ali mlajše odrasle moške.
This type of cancer has usually resulted in death.
Ta oblika raka običajno vodi do smrti bolnika.
All of these patients had also received drugs known as azathioprine or 6-mercaptopurine.
Vsi omenjeni bolniki so prejemali tudi zdravilo azatioprin ali 6- merkaptopurin.
Cancers, other than lymphoma, have also been reported in patients with a specific type of lung disease called Chronic Obstructive Pulmonary Disease (COPD).
Pri bolnikih s posebno vrsto pljučne bolezni, ki jo imenujejo kronična obstruktivna pljučna bolezen (KOPB), so poročali tudi o pojavu drugih vrst raka, ne le limfoma.
Patients with COPD and/or patients who are heavy smokers may be at increased risk for cancer with Remicade treatment.
Bolniki s KOPB in/ ali tisti, ki so težki kadilci, imajo lahko povečano tveganje za nastanek raka pri zdravljenju z zdravilom Remicade.
If you have COPD or are a heavy smoker you should discuss with your doctor whether Remicade is appropriate for you.
Če imate KOPB ali ste težki kadilec, se posvetujte s svojim zdravnikom, ali je zdravilo Remicade primerno za vas.
Using other medicines You need to inform your doctor about any medicine or treatment that you are taking, have been given or are planning to have.
Uporaba drugih zdravil Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Generally, patients who have rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis or psoriasis, already take several medicines to treat their disease such as methotrexate, azathioprine or 6-mercaptopurine.
Bolniki z revmatoidnim artritisom, Crohnovo boleznijo, ulceroznim kolitisom, ankilozirajočim spondilitisom, psoriatičnim artritisom ali psoriazo običajno že prejemajo več zdravil za zdravljenje njihove bolezni, npr. metotreksat, azatioprin ali 6- merkaptopurin.
These medicines may themselves cause side effects.
Tudi ta zdravila lahko povzročijo neželene učinke.
If you get any additional side effects or any new symptoms, please tell your doctor.
Če imate kakršnekoli dodatne neželene učinke ali nove simptome, obvestite svojega zdravnika.
Pregnancy Use of Remicade is not recommended during pregnancy.
Nosečnost Uporaba zdravila Remicade ni priporočljiva v času nosečnosti.
If you are being treated with Remicade, you must avoid getting pregnant by using adequate contraception during your treatment and for at least 6 months after the last Remicade infusion.
Če prejemate zdravilo Remicade, morate med zdravljenjem in vsaj 6 mesecev po zadnji infuziji zdravila preprečiti nosečnost z uporabo ustrezne kontracepcije.
Breast-feeding It is not known if infliximab is excreted in human milk.
Dojenje Ni znano, ali se infliksimab izloča v materino mleko pri človeku.
If you are a nursing mother, you must stop breast-feeding if you are to be given Remicade.
Če dojite, morate prenehati z dojenjem, če boste prejeli zdravilo Remicade.
Before starting breast-feeding, your last treatment with Remicade must be at least 6 months ago.
Dojiti lahko spet začnete šele, ko od zadnje terapije z zdravilom Remicade mine najmanj 6 mesecev.
Special patient groups Due to insufficient data on safety and efficacy, Remicade is not recommended for use in children aged 17 years or younger, except in Crohn’s disease.
Posebne skupine bolnikov Ker ni zadostnih podatkov o njegovi varnosti in učinkovitosti, zdravilo Remicade ni priporočljivo za uporabo pri otrocih, starih 17 let ali manj, razen pri Crohnovi bolezni.
Remicade has not been studied in children with Crohn’s d isease below the age of 6 years.
Zdravila Remicade niso proučevali pri otrocih s Crohnovo boleznijo, mlajših od 6 let.
Specific studies with Remicade have not been conducted in elderly patients, or in patients with hepatic or renal disease.
Specifične študije z zdravilom Remicade niso bile izvedene pri starejših bolnikih niti pri bolnikih z boleznimi jeter ali ledvic.
Driving and using machines It is not known if Remicade affects the ability to drive or use machines.
Vpliv na sposobnost upravljanja vozil in strojev Ni znano, ali zdravilo Remicade vpliva na sposobnost vožnje in upravljanja s stroji.
If you are feeling tired or unwell after receiving Remicade, do not drive or use any tools or machines.
Če ste po prejemu zdravila Remicade utrujeni ali se ne počutite dobro, ne smete voziti ali upravljati s kakršnimikoli stroji.
HOW TO USE REMICADE
KAKO UPORABLJATI ZDRAVILO REMICADE
Remicade is supplied as a powder for concentrate for solution for infusion.
Zdravilo Remicade je na voljo v obliki praška za koncentrat za raztopino za infundiranje.
This means that before Remicade is given to you, it is first dissolved in water for injections.
To pomeni, da bodo zdravilo raztopili v vodi za injekcije, preden ga prejmete.
The resulting solution is then further diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion.
Dobljeno raztopino bodo nato dodatno razredčili z 9 mg/ ml (0, 9%) raztopino natrijevega klorida za infundiranje.
Remicade is given to you in a vein, usually in your arm, over a 2-hour period in a health care facility.
Infuzijo boste dobili v zdravstveni ustanovi in bo trajala 2 uri.
If you are a patient with rheumatoid arthritis, after the third infusion your doctor may decide to give you Remicade over a 1-hour period.
Če sodite med bolnike z revmatoidnim artritisom, se bo vaš zdravnik po tretji infuziji morda odločil, da vam lahko čas infundiranja zdravila Remicade skrajša na 1 uro.
Your doctor or assistant will be monitoring you while you receive your Remicade dose and 1 to 2 hours thereafter.
Vaš zdravnik ali medicinska sestra vas bosta nadzorovala med infuzijo zdravila Remicade in še 1 do 2 uri po njej.
Depending on your disease and if you respond, your doctor will decide on your individual dose and dosing interval.
Zdravnik bo določil individualni odmerek za vas in razmik med posameznimi odmerki glede na vašo bolezen in odziv na zdravljenje.
Treatment may also be continued thereafter.
Prejeli boste lahko še dodatne odmerke, 2 in 6 tednov po prvi infuziji, zdravljenje pa se lahko nadaljuje tudi kasneje.
The total amount of infliximab given to you is based on the dose and your body weight.
Celotna količina infliksimaba, ki jo boste prejeli, bo odvisna od odmerka in vaše telesne mase.
Your doctor will advise you what other medicines you must continue to take while on Remicade.
Vaš zdravnik vam bo svetoval, katera druga zdravila boste morali še naprej jemati med zdravljenjem z zdravilom Remicade.
43 Rheumatoid arthritis:
Revmatoidni artritis:
The recommended starting dose is 3 mg of infliximab for every kg of body weight.
Priporočeni začetni odmerek je 3 mg infliksimaba na kg telesne mase.
Crohn's Disease:
Crohnova bolezen:
The recommended dose for severe, active Crohn's disease is 5 mg of infliximab for every kg of body weight.
Priporočeni odmerek za hudo, aktivno Crohnovo bolezen je 5 mg infliksimaba na kg telesne mase.
The recommended dose for closure of enterocutaneous f istulas is 5 mg of infliximab for every kg of body weight.
Priporočeni odmerek za zaprtje enterokutanih fistul je prav tako 5 mg infliksimaba na kg telesne mase.
Ankylosing spondylitis:
Ankilozirajoči spondilitis:
The recommended dose is 5 mg of infliximab for every kg of body weight.
Priporočeni odmerek je 5 mg infliksimaba na kg telesne mase.
Like all medicines, Remicade can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Remicade neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
However some may be serious and may require treatment.
Večina neželenih učinkov je blagih do zmernih, nekateri pa so lahko resni in je zaradi njih potrebno zdravljenje.
Side effects may appear up to six months after the last infusion.
Neželeni učinki se lahko pojavijo do šest mesecev po zadnji infuziji.
Tell your doctor immediately if you notice any of the following: • pain or tenderness in chest, muscles, joints or jaw • swelling of the hands, feet, ankles, face, lips, mouth or throat which may cause difficulty in swallowing or breathing • hives or other signs of an allergic reaction • fever • rash • itching • shortness of breath with exertion or upon lying down or swelling of the feet
Nemudoma obvestite zdravnika, če opazite katerega od naslednjih znakov: • bolečine ali občutljivost v prsnem košu, mišicah, sklepih ali čeljustih • otekanje dlani, stopal, gležnjev, obraza, ustnic, ust ali žrela, ki lahko povzroči težave s požiranjem ali dihanjem • koprivnico ali druge znake alergijske reakcije • zvišano telesno temperaturo • izpuščaj • srbenje • težave z dihanjem ob naporu ali pri ležanju ter otekanje stopal
Tell your doctor as soon as possible if you notice any of the following: • signs of infection • difficulty breathing and non-productive cough • problems with urination • changes in the way your heart beats, for example, if you notice it beating faster • light-headedness • tiredness • hoarseness • coughing • headache • signs of neurological problems: seizures, tingling or numbness in any part of your body, weakness in arms and/or legs, eye problems, changes in vision • signs of liver or spleen problems: eyes or skin turning yellow, dark-brown coloured urine, upper abdominal pain • loss of weight
Zdravnika tudi obvestite čimprej, če opazite kateregakoli od naslednjih znakov: • znake okužbe • težave z dihanjem in neproduktiven kašelj • težave z uriniranjem • spremembe v bitju srca, npr. hitrejše bitje srca • omotico 46 • utrujenost • hripavost • kašelj • glavobol • znaki nevroloških težav: epileptični napadi, pojav mravljincev ali odrevenelosti v kateremkoli delu telesa, oslabelost rok ali nog, očesne težave, spremembe vida • znaki težav z jetri ali vranico: porumenitev oči ali kože, temno rjavo obarvan seč, bolečine v zgornjem delu trebuha • izgubo telesne mase • nočno potenje
The symptoms described above can be signs of the below listed side effects, which have been observed with Remicade.
Navedeni simptomi so lahko znaki spodaj naštetih neželenih učinkov, ki so jih opažali pri uporabi zdravila Remicade.
Common side effects (likely to occur in fewer than 1 in 10 patients): headache, dizziness, nausea, abdominal symptoms, allergic reactions, rash, urticaria, viral infections (for example herpes), respiratory infections (cold, sinus infections, bronchitis, pneumonia).
Pogosti neželeni učinki (ki se bodo verjetno pojavili pri manj kot 1 na 10 bolnikov): glavobol, omotica, slabost, trebušni simptomi, alergijske reakcije, izpuščaj, urtikarija, virusne okužbe (npr. herpes), okužbe dihal (prehlad, okužbe sinusov, bronhitis, pljučnica).
Depression, agitation, sleep disturbances, impaired wound heeling, bacterial infections, (for example tuberculosis, urinary tract infections, deep skin infections, sepsis), fungal infections, asthma, abnormal liver function, low blood cell counts including anemia, worsening of demyelinating nerve disease, autoimmune disease activation (SLE, lupus), worsening of heart failure, hair loss, bleedings, allergic anaphylactic reactions, injection site reactions.
Občasni neželeni učinki (ki se bodo verjetno pojavili pri manj kot 1 na 100 bolnikov): depresija, vznemirjenost, motnje spanja, slabo celjenje ran, bakterijske okužbe (npr. tuberkuloza, okužbe sečil, globoke okužbe kože, sepsa), glivične okužbe, astma, nenormalno delovanje jeter, znižano število krvnih celic, vključno z anemijo, poslabšanje demielinizirajočih bolezni živčevja, aktivacija avtoimunskih bolezni (SLE- sistemski lupus eritematozus), poslabšanje srčnega popuščanja, izpadanje las, krvavitve, alergijske anafilaktične reakcije, reakcije na mestu injiciranja.
Gastrointestinal bleedings or perforation, circulatory failure, multiple sclerosis, lymphoma.
Redki neželeni učinki (ki se bodo verjetno pojavili pri manj kot 1 na 1000 bolnikov): krvavitve iz prebavil ali perforacija prebavil, odpoved krvnega obtoka, multipla skleroza, limfom.
Your doctor may also do tests to examine your liver function and/or blood values.
Zdravnik vas bo lahko napotil tudi na preiskave delovanja jeter in/ ali krvne slike.
If any of the side effects gets serious or if you notice any side effects that are not listed in this leaflet, please tell your doctor.
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželen učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika.
HOW TO STORE REMICADE
SHRANJEVANJE ZDRAVILA REMICADE
• Keep out of the reach and sight of children. • Do not use Remicade after the expiry date which is stated on the label and the carton.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatlici.
The expiry date refers to the last day of that month. • Store in a refrigerator (2°C – 8°C).
Shranjujte v hladilniku (2 °C in 8 °C).
The reconstituted diluted infusion solution is stable for 24 hours at 25°C, but for bacteriological reasons it is recommended to use it as soon as possible.
Rekonstituirana razredčena raztopina zdravila Remicade za infundiranje je stabilna 24 ur pri 25 °C,, vendar je iz bakterioloških razlogov priporočljivo, da jo uporabite čimprej.
The infusion is to be started within 3 hours of reconstitution and dilution.
Infuzijo morate začeti v roku 3 ur po rekonstituciji in redčenju.
When reconstitution and dilution are performed under aseptic conditions, Remicade infusion solution can be used within 24 hours if stored at 2°C to 8°C.
Če sta rekonstitucija in redčenje opravljena v aseptičnih pogojih, smete raztopino zdravila Remicade za infundiranje uporabiti v roku 24 ur, če je shranjena pri temperaturi od 2 ° do 8 °C.
Your doctor or other healthcare professionals will take care of handling and storing Remicade.
Zdravnik ali drugi zdravstveni delavci bodo poskrbeli za shranjevanje zdravila in rokovanje z njim.
Remicade will not be given to you if there are opaque particles, discolouration or other foreign particles present.
Zdravila Remicade ne boste prejeli, če raztopina vsebuje neprosojne delce, če je obarvana ali če vsebuje druge tuje delce.
What Remicade contains • The active substance is infliximab.
47 Kaj vsebuje zdravilo Remicade
Each vial contains 100 mg of infliximab.
Vsaka viala vsebuje 100 mg infliksimaba.
After reconstitution each ml contains 10 mg of infliximab. • The other ingredients are sucrose, polysorbate 80, monobasic sodium phosphate and dibasic sodium phosphate.
vsak ml vsebuje 10 mg infliksimaba.
What Remicade looks like and contents of the pack Remicade is supplied as a glass vial containing a powder.
- Pomožne snovi so saharoza, polisorbat 80, natrijev hidrogenfosfat, natrijev dihidrogenfosfat.
Remicade is produced in packs of 1, 2, 3, 4 or 5 vials, but not all pack sizes may be marketed.
Zdravilo Remicade pakirano po 1, 2, 3, 4 ali 5 vial, vendar na trgu ni vseh navedenih pakiranj.
Marketing Authorisation Holder and Manufacturer Centocor B.V.
Imetnik dovoljenja za promet z zdravilom in izdelovalec zdravila:
45 Einsteinweg 101 2333 CB Leiden The Netherlands For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
Einsteinweg 101 2333 CB Leiden Nizozemska
2 BG-София 1407 Tел.: +359 2 806 3030
2 BG- София 14071504 Tел.: +359 2 806 3030
Nederland Walmolen 1NL-3994 DL Houten Tel: + 31-(0)800 999 90 00
Nederland Walmolen 1NL- 3994 DL Houten Tel: + 31 - (0) 800 999 90 00
Ελλάδα Αγίου Δημητρίου 63 GR-174 55 Άλιμος Τηλ: + 30-210 98 97 300
Ελλάδα Αγίου Δημητρίου 63 GR- 174 55 Άλιμος
Taśmowa 7 PL-02-677 Warszawa Tel.: + 48-(0)22 478 41 50
Taśmowa 7 PL- 02- 677 Warszawa
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http://www.emea.europa.eu
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http: // www. emea. europa. eu
47 THE FOLLOWING INFORMATION IS INTENDED FOR MEDICAL OR HEALTHCARE PROFESSIONALS ONLY:
49 NAVODILA SO NAMENJENA ZDRAVSTVENIM DELAVCEM
Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 1.2 micrometer or less).
Uporabite lahko le infuzijske komplete, opremljene z linijskim, sterilnim, apirogenim filtrom, ki le malo veže beljakovine (velikost por 1, 2 mikrometra ali manj).
When reconstitution and dilution are performed under aseptic conditions, Remicade infusion solution can be used within 24 hours if stored at 2°C to 8°C.
Če sta rekonstitucija in redčenje opravljena v aseptičnih pogojih, smete infuzijsko raztopino zdravila Remicade uporabiti v roku 24 ur, če je shranjena pri temperaturi od 2 ° do 8 °C.
Do not store any un used portion of the infusion solution for reuse.
Neporabljenega ostanka raztopine za infundiranje ne smete shraniti za poznejšo uporabo.
Any unused product or waste material; should be disposed of in accordance with local requirements.
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Renagel is a medicine containing the active substance sevelamer.
Renagel je zdravilo, ki vsebuje zdravilno učinkovino sevelamer.
It is available as white oval tablets (400 mg and 800 mg).
Na voljo je v obliki belih ovalnih tablet (400 mg in 800 mg).
Renagel is used to control hyperphosphataemia (high blood phosphate levels) in adult patients on dialysis (a blood clearance technique).
Zdravilo Renagel se uporablja za uravnavanje hiperfosfatemije (zvišane koncentracije fosfatov v krvi) pri odraslih bolnikih na dializi (tehniki čiščenja krvi).
It can be used in patients undergoing haemodialysis (using a blood filtration machine) or peritoneal dialysis (where fluid is pumped into the abdomen and an internal body membrane filters the blood).
Lahko se uporablja pri bolnikih, ki prejemajo hemodializo (z uporabo naprave za filtriranje krvi) ali peritonealno dializo (pri čemer se tekočina črpa v trebuh, notranja telesna membrana pa filtrira kri).
Renagel should be used with other treatments such as calcium supplements and vitamin D3 to control the development of bone disease.
Zdravilo Renagel je treba uporabljati z drugimi zdravili, na primer z dodatki kalcija in vitamina D3 za nadzor razvoja kostne bolezni (osteodistrofije).
The recommended starting dose of Renagel depends on the level of phosphate in the blood and ranges from 800 to 1,600 mg three times a day.
Priporočeni začetni odmerek zdravila Renagel je odvisen od koncentracije fosfatov v krvi in znaša od 800 do 1600 mg trikrat dnevno.
The dose of Renagel should be adjusted to ensure that the blood phosphate level stays below 1.76 mmol/ l.
Odmerek zdravila Renagel je treba prilagoditi tako, da raven fosfatov v krvi ostane pod 1, 76 mmol/ l.
Patients should take Renagel tablets whole with meals and stick to their prescribed diets.
Bolniki morajo tablete zdravila Renagel jemati cele ob obroku in se držati predpisanih diet.
The safety and effectiveness of Renagel have not been established in children.
Varnost in učinkovitost zdravila Renagel pri otrocih ni ugotovljena.